
Topic
Medical Oncology
Podcasts
Tumor Board # 92Nov 17, 2026Multidisciplinary Approaches in Pancreatic Cancer Care

At Cedars-Sinai, the time from a pancreatic cancer diagnosis to the first dose of chemotherapy fell from about a month to 14 days, and trial enrollment nearly tripled, once every specialist started seeing the patient in the same room on the same day. On this episode of the BackTable GI Oncology Creator Weekend™, medical oncologist Dr. Andrew Hendifar of Cedars-Sinai is joined by surgical oncologist Dr. Adam Yopp, chief of surgical oncology at UT Southwestern, and GI medical oncologist Dr. Arsen Osipov of Cedars-Sinai to compare how their same-day multidisciplinary clinics run and what every clinic needs, from an experienced pancreatic surgeon and a radiation oncologist to genetic counseling, an early dietitian visit, and supportive care. They also explain how virtual tumor boards, same-week biopsy slots, and outreach networks bring community oncologists in Texas and California into the plan, and weigh whether pancreatic cancer care should be regionalized, as it is in parts of Canada.
Tumor Board # 91Nov 12, 2026Direct Contracting in Healthcare

"No cancer patient ever got healthier because their claim was denied and delayed," Mark Cuban says, and his answer is a contract that starts by trusting the doctor. On this episode of the BackTable Podcast, Dr. Ruchika Talwar, value-based care leader at Vanderbilt University Medical Center, talks with Mark Cuban, entrepreneur and founder of Mark Cuban Cost Plus Drug Company, about who actually sets the price of care in the United States. For oncology teams, he describes how an employer with access to its own claims data can contract directly with an oncology center for its employees with cancer. He also traces how a transparent pharmacy model led to Cost Plus Wellness, an open source library of direct contracts between self-insured employers and providers, and why he believes the contract, not the published price, is where the real problems hide.
Tumor Board # 90Nov 10, 2026Metastatic Pancreatic Cancer: A New Era of Treatment?

A drug that nearly doubles overall survival in metastatic pancreatic cancer is something Dr. Arsen Osipov says the field has never seen before, and it is why he calls the pan-RAS inhibitor daraxonrasib a paradigm shift on the scale of the first immunotherapy approvals. On this episode of the BackTable GI Oncology Creator Weekend™, host Dr. Andrew Hendifar leads a tumor board on metastatic pancreatic cancer with fellow GI oncologists Dr. Arsen Osipov and Dr. Daniel Ahn. They start with the workup. A CT of the chest, abdomen, and pelvis is usually enough, and a PET rarely changes management. They also cover what to do when a patient does not make CA 19-9, the debate over routine DPYD testing before 5-FU, and why every patient gets molecular profiling.
Tumor Board # 89Nov 2, 2026Perioperative Management of Pancreatic Cancer

Most patients with localized pancreatic cancer already have disease the scans cannot see, which is why these GI oncologists treat chemotherapy before surgery as a test of tumor biology. On this episode of the BackTable GI Oncology Creator Weekend™, medical oncologist Dr. Andrew Hendifar leads a tumor board with GI medical oncologists Dr. Arsen Osipov and Dr. Daniel Ahn on the perioperative management of pancreatic cancer. They explain why nearly every patient with localized disease now starts with chemotherapy rather than surgery, which red flags such as an elevated CA 19-9, enlarged lymph nodes, or profound weight loss point to hidden micrometastatic disease, and why an 80-year-old can still be a candidate for FOLFIRINOX when biological age outweighs chronological age.
Tumor Board # 88Oct 30, 2026Beyond First-Line Therapy: Treatment Strategies for Advanced Neuroendocrine Tumors

Few oncologists know neuroendocrine tumors from both sides of the exam table: first as a patient diagnosed during training, and now as the doctor treating them. This physician brings both perspectives to one pressing question: when a tumor progresses on a somatostatin analog, what comes next? On this episode of BackTable Tumor Board, Dr. Aman Chauhan, a medical oncologist at UCSF, interviews Dr. Mark Lewis, director of gastrointestinal oncology at Intermountain Health in Salt Lake City, about treatment strategies for advanced neuroendocrine tumors beyond first-line therapy. They start with what progression on a somatostatin analog really means, how grade, Ki-67, primary site, and the pace of liver disease shape the next step, and why observation is sometimes the right call. Dr. Lewis explains how he sets expectations for PRRT after NETTER-1 and NETTER-2, including the small but real risk of secondary myelodysplasia and leukemia.
Tumor Board # 87Oct 27, 2026Diagnosis & Management of Advanced HER2-Negative Upper GI Cancers

Five years ago, first-line treatment for advanced HER2-negative gastroesophageal cancer meant chemotherapy; today claudin 18.2, PD-L1, and mismatch repair status shape the plan, often for a patient who cannot afford to wait for the results. On this episode of the BackTable GI Oncology Creator Weekend™, host Dr. Kate Baker interviews medical oncologists Dr. Ronan Hsieh and Dr. Dani Castillo about the diagnosis and management of advanced HER2-negative upper GI cancers. They discuss the biomarker workup at diagnosis, next-generation sequencing and liquid biopsy, when to biopsy metastatic sites, and why both guests start chemotherapy before every result is available.
Tumor Board # 86Oct 20, 2026Optimizing Treatment for Advanced HER2-Positive Upper GI Cancers

When a gastroesophageal tumor is positive for HER2, PD-L1, and claudin 18.2, which target should you treat first and how do you decide? On this episode of the BackTable GI Oncology Creator Weekend™, host Dr. Kate Baker interviews Dr. Geoffrey Buckle, a GI medical oncologist at UCSF, and Dr. Ronan Hsieh, a GI oncologist at Swedish Cancer Institute in Seattle, for a breakdown of therapy selection and management in advanced HER2-positive upper GI cancers. They start with a detailed case, covering biomarker workup, how to choose a first-line regimen without head-to-head data, and how to manage nutrition and palliative radiation when a patient presents with dysphagia and weight loss.
Tumor Board # 85Oct 13, 2026Perioperative Management in Upper GI Cancers

How do you choose between perioperative chemotherapy and trimodality therapy for a patient with localized upper GI cancer, and what has the newest data actually settled? On this episode of BackTable Tumor Board, host Dr. Kate Baker interviews Dr. Dani Castillo, a medical oncologist at City of Hope in Duarte, California, and Dr. Alexandra Gangi, a gastrointestinal surgical oncologist at Cedars-Sinai in Los Angeles, about everything that happens between a new diagnosis and a resection in localized esophageal, gastroesophageal junction and gastric cancer. They cover diagnostic workup, Siewert classification, staging laparoscopy, histology, biomarker testing, surgical candidacy, and the challenges of nutrition and prehabilitation.
Tumor Board # 84Oct 6, 2026Managing Refractory MSS-MCRC: Advanced Treatment Strategies

What options remain when a patient with microsatellite stable metastatic colorectal cancer (MSS mCRC) has progressed through every standard line of chemotherapy? On this episode of BackTable Tumor Board, Dr. Jun Gong is joined by Dr. Ibrahim Sahin and Dr. Sandra Algaze to explore the nuances of late-line management in MSS-mCRC. They discuss how to approach oxaliplatin retreatment and anti-EGFR rechallenge, the growing role of liquid biopsy and biomarker-driven selection, and the practicalities of DPYD testing after recent guideline changes.
Tumor Board # 83Sep 29, 2026Molecular-Driven Therapies in Colorectal Cancer

Which molecular alterations in colorectal cancer now change treatment and how quickly do you need the results to make the right call? On this episode of BackTable Tumor Board, Dr. Jun Gong interviews Dr. Ibrahim Sahin and Dr. Sandra Algaze about the latest advances in molecular-driven therapy across adjuvant and metastatic settings. They cover aspirin in PI3K-altered disease, the shift toward early next-generation sequencing, and the operational realities of systematic profiling at diagnosis.
Urology # 332Sep 29, 2026The Basics of Advanced Prostate Cancer Management for Urologists

What does a urologist actually need to know to confidently manage advanced prostate cancer in the clinic? On this episode of BackTable Urology, host Dr. Ruchika Talwar interviews Dr. Kristen Scarpato, director of the advanced prostate cancer clinic at Vanderbilt University Medical Center, and Dr. Jason Hafron, chief medical officer of the Michigan Institute of Urology. They break down how the landscape has shifted, why more patients stay in urology for treatment, and how to select and monitor therapy based on disease state, comorbidities, and patient goals.
Tumor Board # 82Sep 22, 2026Advances in Perioperative Colorectal Cancer Management

How much of perioperative colorectal cancer management has changed in just one year, and what does it mean for patient care? On this episode of BackTable Tumor Board, Dr. Jun Gong is joined by Dr. Ibrahim Sahin and Dr. Alexandra Gangi to review the latest practice-changing data in colon and rectal cancer. They discuss observation versus maintenance immunotherapy in MSI-high disease, the CHALLENGE trial's surprising results on exercise and disease-free survival, and the evolving role of ctDNA and local therapies after liver metastasis resection.
Tumor Board # 81Sep 15, 2026CNS Disease in Breast Cancer: Clinical Management & Strategies

How should a breast cancer team manage central nervous system (CNS) disease now that systemic therapy, radiation, and surgery all compete for the first move? On this episode of BackTable Tumor Board, host Dr. Lindsay Peterson interviews Dr. Barbara O'Brien, neuro-oncologist at MD Anderson, about diagnosis, sequencing, and follow-up for CNS disease in breast cancer. They discuss risk by subtype, when to image and screen, and the importance of multidisciplinary workup for new brain metastases, as well as how to choose and sequence local and systemic options.
Tumor Board # 80Sep 8, 2026Scaling Community CAR-T: Operational Lessons & Future Directions

How does delivering CAR-T in the community change patient care, and what has to happen next for these programs to scale? On this episode of the BackTable Tumor Board Podcast, host Aaron Lyss interviews Dr. Mike Byrne, hematologist at Tennessee Oncology and medical director for cellular therapy at OneOncology, about operational lessons and future directions for outpatient CAR-T therapy. They discuss the impact of faster time to treatment, building trust through local relationships, and the weekly pipeline management that keeps the program moving.
Women's Health # 132Sep 1, 2026Gynecologic Cancer Surveillance: Best Practices & Updates

Does catching cancer earlier with surveillance always translate to better outcomes for gynecologic cancer patients? On this episode of BackTable, hosts Dr. Mona Guo and Dr. Marcia Ciccone interview Dr. Ritu Salani, Professor of OBGYN at UCLA and lead author of the updated SGO surveillance clinical practice statements. They discuss how post–curative-intent surveillance has evolved amid limited prospective evidence, review the latest guidelines, and highlight the real-world challenges of balancing early detection, patient safety, and cost.
Tumor Board # 79Sep 1, 2026Gynecologic Cancer Surveillance: Best Practices & Updates

Does catching cancer earlier with surveillance always translate to better outcomes for gynecologic cancer patients? On this episode of BackTable, hosts Dr. Mona Guo and Dr. Marcia Ciccone interview Dr. Ritu Salani, Professor of OBGYN at UCLA and lead author of the updated SGO surveillance clinical practice statements. They discuss how post–curative-intent surveillance has evolved amid limited prospective evidence, review the latest guidelines, and highlight the real-world challenges of balancing early detection, patient safety, and cost.
Tumor Board # 78Aug 25, 2026Developing CAR T-Cell Programs in Community Oncology

Where does access to cell therapy actually break down, and can community practices close the gap? On this episode of BackTable Tumor Board, host Aaron Lyss interviews Dr. Mike Byrne, a hematologist at Tennessee Oncology, about the challenges and successes of building an outpatient CAR T program in the community setting. They discuss the critical stakeholder relationships, operational and financial structures, and patient pathways that enable a physician-owned practice to offer cellular therapy outside a hospital system.
Tumor Board # 77Aug 18, 2026AI's Impact on Oncology Practice

Where is AI already making oncology practice more efficient, and where does human expertise remain irreplaceable? In this episode of BackTable Tumor Board, medical oncologists Dr. Kate Baker and clinical data expert Larry Bilbrey discuss how AI is improving oncology workflow, such as scribing and information retrieval, but is far from replacing clinicians, especially for hands-on care.
Tumor Board # 76Aug 11, 2026GU Oncology: ASCO Highlights & Impacts on Practice

Is GU oncology entering a new era of early intensification and precision therapy? On this episode of the BackTable Tumor Board Podcast, Dr. Katy Beckermann and Dr. Alan Tan break down the latest GU oncology highlights from ASCO, including key updates in prostate, renal cell, and urothelial carcinoma. They discuss new data supporting HRR/BRCA-focused therapy in HSPC, the importance of early biomarker testing, and ongoing debates about overtreatment and real-world practice impact.
Tumor Board # 75Aug 4, 2026Applying CheckMate 8HW: Practical Updates for MSI-High CRC

Is it time to rethink the definition of “cure” for stage IV colorectal cancer? In this episode of BackTable Tumor Board, medical oncologist Jun Gong interviews Dr. Cathy Eng about updates from the phase III CheckMate-8HW trial in centrally confirmed MSI-high/dMMR metastatic colorectal cancer, comparing nivolumab/ipilimumab, nivolumab, and chemotherapy. They discuss initial findings demonstrating improved progression-free survival and response rates with combination immunotherapy, as well as safety considerations and how comorbidities and frailty guide the choice between single-agent and combination regimens.
Tumor Board # 74Jul 28, 2026Systemic Therapy Strategies for Treating Neuroendocrine Tumors

What first-line therapies should be considered for patients with higher-grade, metastatic neuroendocrine tumors (NETs)? In this new episode of BackTable Tumor Board, Drs. Lingling Du, Chih-Yi Liao, and Robert Ramirez discuss the use of systemic or radioligand therapies for metastatic well-differentiated NETs.
Tumor Board # 73Jul 21, 2026Comprehensive Care in Breast Cancer Survivorship

When breast cancer treatment ends, recurrence surveillance can easily overshadow the symptoms and concerns that continue to affect daily life. In this episode of the BackTable Tumor Board Podcast, Dr. Kate Baker and Dr. Lindsay Peterson discuss how effective survivorship care can address recurrence anxiety, endocrine therapy toxicities, bone health, sexual health, and the broader emotional and practical needs of patients after treatment.
Tumor Board # 72Jul 14, 2026Optimizing Liver-Directed Interventions for Neuroendocrine Tumors

What factors come into play when deciding whether to use liver-directed therapy or systemic therapies for neuroendocrine tumors? In this episode of the BackTable Tumor Board Podcast, Dr. Lingling Du, Dr. Chih-Yi Liao, and Dr. Abdul Khan discuss the structure of a multidisciplinary tumor board and how they approach decision-making for patients with neuroendocrine tumors. The conversation explores who benefits most from liver-directed therapy, optimal timing for intervention, and the importance of individualized treatment planning.
Urology # 314Jul 7, 2026Exploring PARP Inhibitor Combinations in Prostate Cancer

With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for advanced prostate cancer? In this episode of BackTable Urology, Dr. Alan Tan is joined by Dr. Rana McKay and Dr. Emmanuel Antonarakis to discuss how evolving evidence, patient selection, timing, toxicity, and genetic testing are shaping the use of PARP inhibitor combinations in clinical practice.